This is a news story, published by BGR, that relates primarily to the University of California, San Diego’s School of Medicine news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from BGR, you can click here:
more news from BGROtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
sleep apnea drug tirzepatide. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest proper therapeutic sleep apnea drug news, sleep apnea news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
new sleep apnea drugBGR
•72% Informative
Tirzepatide has been so effective in its first trials that it could become the first therapeutic to actually treat sleep apnea, a condition that affects more than 936 million people worldwide.
Researchers from the University of California, San Diego’s School of Medicine tested 469 patients with OSA and weight issues with the drug.
VR Score
65
Informative language
61
Neutral language
11
Article tone
informal
Language
English
Language complexity
46
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
3
Source diversity
2
Affiliate links
no affiliate links